[Successful cancer therapy: chance and challenges.]

Greil, R; Hiddemann, W; Dtsch Med Wochenschr. 2013; 138(41): 2083

Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.

Gampenrieder, SP; Rinnerthaler, G; Greil, R; J Oncol. 2013; 2013: 732047

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

Melchardt, T; Weiss, L; Greil, R; Egle, A; Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 193-196.

ASH 2012 update chronic lymphocytic leukemia—the best is yet to come

Weiss, L; Melchardt, T; Greil, R; Hopfinger, G; Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 177-180.

Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT.

Auberger, J; Graziadei, I; Clausen, J; Vogel, W; Nachbaur, D; Bone Marrow Transplant. 2013; 48(1): 159-160.

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

Lutzny, G; Kocher, T; Schmidt-Supprian, M; Rudelius, M; Klein-Hitpass, L; Finch, AJ; Dürig, J; Wagner, M; Haferlach, C; Kohlmann, A; Schnittger, S; Seifert, M; Wanninger, S; Zaborsky, N; Oostendorp, R; Ruland, J; Leitges, M; Kuhnt, T; Schäfer, Y; Lampl, B; Peschel, C; Egle, A; Ringshausen, I; Cancer Cell. 2013; 23(1):77-92

Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].

Seitz, S; Buchholz, S; Schally, AV; Jayakumar, AR; Weber, F; Papadia, A; Rick, FG; Szalontay, L; Treszl, A; Köster, F; Ortmann, O; Hohla, F; Anticancer Drugs. 2013; 24(2):150-157

The occurrence of dental caries is associated with atherosclerosis.

Glodny, B; Nasseri, P; Crismani, A; Schoenherr, E; Luger, AK; Bertl, K; Petersen, J Clinics (Sao Paulo). 2013; 68(7):946-953

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang, I; Brodowicz, T; Ryvo, L; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Messinger, D; Zielinski, C; Lancet Oncol. 2013; 14(2):125-133

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma.

Ludwig, H; Viterbo, L; Greil, R; Masszi, T; Spicka, I; Shpilberg, O; Hajek, R; Dmoszynska, A; Paiva, B; Vidriales, MB; Esteves, G; Stoppa, AM; Robinson, D; Ricci, D; Cakana, A; Enny, C; Feng, H; van de Velde, H; Harousseau, JL; J Clin Oncol. 2013; 31(2):247-255